Drug
AG 120
AG 120: highest development phase Phase 3, developed by Servier. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| AG-120 NCT03173248 | Phase 3 | Newly Diagnosed Acute Myeloid Leukemia (AML) |
| AG-120 NCT02632708 | Phase 1 | Newly Diagnosed Acute Myeloid Leukemia (AML) |
Latest
No recent events.
Follow AG 120 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.